Study · Not a test of the peptide alone · 2009

14 results

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH

The Journal of clinical endocrinology and metabolism7 Jul 2009Cited by 127 (Europe PMC)

PMID19584192DOI10.1210/jc.2008-2719PepBankPUB-19584192

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In women with osteoporosis, adding teriparatide to alendronate produced a smaller PINP increase than switching to teriparatide.
In plain wordsIn women with osteoporosis, PINP increased less with teriparatide plus alendronate than after switching to teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePINP with continued versus stopped alendronate
Study
n: not reported in source
Comparator
Switch from alendronate to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
PINP increase
64%
Add, 6 months
PINP increase
401%
Switch, 6 months
Source sentences
Summary
In the alendronate stratum, increases in BTM were smaller in the Add vs. Switch group [6-month PINP (64 vs. 401%); bone ALP (15 vs. 71%); betaCTX (27 vs. 250%); all P < 0.001].
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419201
02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In women with osteoporosis, adding teriparatide to alendronate produced a smaller bone ALP increase than switching to teriparatide.
In plain wordsIn women with osteoporosis, bone ALP increased less with teriparatide plus alendronate than after switching to teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone ALP with continued versus stopped alendronate
Study
n: not reported in source
Comparator
Switch from alendronate to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Bone ALP increase
15%
Add, 6 months
Bone ALP increase
71%
Switch, 6 months
Source sentences
Summary
In the alendronate stratum, increases in BTM were smaller in the Add vs. Switch group [6-month PINP (64 vs. 401%); bone ALP (15 vs. 71%); betaCTX (27 vs. 250%); all P < 0.001].
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419202
03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In women with osteoporosis, adding teriparatide to alendronate produced a smaller betaCTX increase than switching to teriparatide.
In plain wordsIn women with osteoporosis, betaCTX increased less with teriparatide plus alendronate than after switching to teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBetaCTX with continued versus stopped alendronate
Study
n: not reported in source
Comparator
Switch from alendronate to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
BetaCTX increase
27%
Add, 6 months
BetaCTX increase
250%
Switch, 6 months
Source sentences
Summary
In the alendronate stratum, increases in BTM were smaller in the Add vs. Switch group [6-month PINP (64 vs. 401%); bone ALP (15 vs. 71%); betaCTX (27 vs. 250%); all P < 0.001].
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419203
04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, total hip BMD increased more with teriparatide plus alendronate than switching to teriparatide at 6 months.
In plain wordsIn women with osteoporosis, hip bone density increased more with teriparatide plus alendronate than switching to teriparatide at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD at 6 months with alendronate
Study
n: not reported in source
Comparator
Switch from alendronate to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD change
1.4%
Add, 6 months
Total hip BMD change
−0.8%
Switch, 6 months
Source sentences
Summary
However, at 6 months, total hip BMD increased more in the Add vs. Switch group (1.4 vs. -0.8%; P = 0.002).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419204
05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, lumbar spine BMD increased more with teriparatide plus alendronate than switching to teriparatide at 18 months.
In plain wordsIn women with osteoporosis, spine bone density increased more with teriparatide plus alendronate than switching to teriparatide at 18 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD at 18 months with alendronate
Study
n: not reported in source
Comparator
Switch from alendronate to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD increase
8.4%
Add
Lumbar spine BMD increase
4.8%
Switch
Source sentences
Summary
In the Add vs. Switch group, 18-month BMD increments were higher in lumbar spine (8.4 vs. 4.8%; P = 0.003) and total hip (3.2 vs. 0.9%; P = 0.02), but not in femoral neck (2.7 vs. 2.3%; P = 0.75).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419205
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, total hip BMD increased more with teriparatide plus alendronate than switching to teriparatide at 18 months.
In plain wordsIn women with osteoporosis, hip bone density increased more with teriparatide plus alendronate than switching to teriparatide at 18 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD at 18 months with alendronate
Study
n: not reported in source
Comparator
Switch from alendronate to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD increase
3.2%
Add
Total hip BMD increase
0.9%
Switch
Source sentences
Summary
In the Add vs. Switch group, 18-month BMD increments were higher in lumbar spine (8.4 vs. 4.8%; P = 0.003) and total hip (3.2 vs. 0.9%; P = 0.02), but not in femoral neck (2.7 vs. 2.3%; P = 0.75).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419206
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, femoral neck BMD increases did not differ significantly between teriparatide plus alendronate and switching to teriparatide.
In plain wordsIn women with osteoporosis, femoral neck bone density increases were similar with teriparatide plus alendronate and switching to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD at 18 months with alendronate
Study
n: not reported in source
Comparator
Switch from alendronate to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD increase
2.7%
Add
Femoral neck BMD increase
2.3%
Switch
Source sentences
Summary
In the Add vs. Switch group, 18-month BMD increments were higher in lumbar spine (8.4 vs. 4.8%; P = 0.003) and total hip (3.2 vs. 0.9%; P = 0.02), but not in femoral neck (2.7 vs. 2.3%; P = 0.75).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419207
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In women with osteoporosis, adding teriparatide to raloxifene produced a smaller PINP increase than switching to teriparatide.
In plain wordsIn women with osteoporosis, PINP increased less with teriparatide plus raloxifene than after switching to teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePINP with continued versus stopped raloxifene
Study
n: not reported in source
Comparator
Switch from raloxifene to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
PINP increase
131%
Add, 6 months
PINP increase
259%
Switch, 6 months
Source sentences
Summary
In the raloxifene stratum, increases in BTM were also smaller in the Add vs. Switch group [6-month PINP (131 vs. 259%; P < 0.001), bone ALP (31 vs. 44%; P = 0.035), and betaCTX (67 vs. 144%; P = 0.001)].
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419208
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In women with osteoporosis, adding teriparatide to raloxifene produced a smaller bone ALP increase than switching to teriparatide.
In plain wordsIn women with osteoporosis, bone ALP increased less with teriparatide plus raloxifene than after switching to teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone ALP with continued versus stopped raloxifene
Study
n: not reported in source
Comparator
Switch from raloxifene to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Bone ALP increase
31%
Add, 6 months
Bone ALP increase
44%
Switch, 6 months
Source sentences
Summary
In the raloxifene stratum, increases in BTM were also smaller in the Add vs. Switch group [6-month PINP (131 vs. 259%; P < 0.001), bone ALP (31 vs. 44%; P = 0.035), and betaCTX (67 vs. 144%; P = 0.001)].
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419209
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In women with osteoporosis, adding teriparatide to raloxifene produced a smaller betaCTX increase than switching to teriparatide.
In plain wordsIn women with osteoporosis, betaCTX increased less with teriparatide plus raloxifene than after switching to teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBetaCTX with continued versus stopped raloxifene
Study
n: not reported in source
Comparator
Switch from raloxifene to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
BetaCTX increase
67%
Add, 6 months
BetaCTX increase
144%
Switch, 6 months
Source sentences
Summary
In the raloxifene stratum, increases in BTM were also smaller in the Add vs. Switch group [6-month PINP (131 vs. 259%; P < 0.001), bone ALP (31 vs. 44%; P = 0.035), and betaCTX (67 vs. 144%; P = 0.001)].
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419210
11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, total hip BMD increased more with teriparatide plus raloxifene than switching to teriparatide at 6 months.
In plain wordsIn women with osteoporosis, hip bone density increased more with teriparatide plus raloxifene than switching to teriparatide at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD at 6 months with raloxifene
Study
n: not reported in source
Comparator
Switch from raloxifene to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD increase
1.8%
Add
Total hip BMD increase
0.5%
Switch
Source sentences
Summary
At 6 months, total hip BMD increase was greater in the Add vs. Switch group (1.8 vs. 0.5%; P = 0.028).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419211
12HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, lumbar spine BMD increases did not differ significantly between teriparatide plus raloxifene and switching to teriparatide.
In plain wordsIn women with osteoporosis, spine bone density increases were similar with teriparatide plus raloxifene and switching to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine BMD at 18 months with raloxifene
Study
n: not reported in source
Comparator
Switch from raloxifene to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD increase
9.2%
Add
Lumbar spine BMD increase
8.1%
Switch
Source sentences
Summary
At 18 months, increases in lumbar spine (9.2 vs. 8.1%), total hip (2.8 vs. 1.8%), and femoral neck (3.8 vs. 2.2%) were not significantly different between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419212
13HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, total hip BMD increases did not differ significantly between teriparatide plus raloxifene and switching to teriparatide.
In plain wordsIn women with osteoporosis, hip bone density increases were similar with teriparatide plus raloxifene and switching to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD at 18 months with raloxifene
Study
n: not reported in source
Comparator
Switch from raloxifene to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD increase
2.8%
Add
Total hip BMD increase
1.8%
Switch
Source sentences
Summary
At 18 months, increases in lumbar spine (9.2 vs. 8.1%), total hip (2.8 vs. 1.8%), and femoral neck (3.8 vs. 2.2%) were not significantly different between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419213
14HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, femoral neck BMD increases did not differ significantly between teriparatide plus raloxifene and switching to teriparatide.
In plain wordsIn women with osteoporosis, femoral neck bone density increases were similar with teriparatide plus raloxifene and switching to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD at 18 months with raloxifene
Study
n: not reported in source
Comparator
Switch from raloxifene to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD increase
3.8%
Add
Femoral neck BMD increase
2.2%
Switch
Source sentences
Summary
At 18 months, increases in lumbar spine (9.2 vs. 8.1%), total hip (2.8 vs. 1.8%), and femoral neck (3.8 vs. 2.2%) were not significantly different between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, open-label trial.Patients and interventionsPostmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1958419214

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 4NCT04467983

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Hospital for Special Surgery, New Yorkn = 701 Feb 2021 to est. 31 Dec 2026

Osteoporosis, Postmenopausal

Trial page ClinicalTrials.govUpdated 13 Oct 2026

CompletedPhase 4NCT00079924